Videos

Advanced Squamous Non-Small Cell Lung Cancer

Nuances in Treating Squamous Cell Lung Cancer

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses options for treating melanoma after the use of targeted therapies and immunotherapy. 

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Richard M. Stone, MD, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).

Hope S. Rugo, MD, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.

A Continuum of Care for Metastatic CRC

Manish A. Shah, MD, discusses the HERACLES clinical trial, which explored treatment with trastuzumab (Herceptin) and lapatinib (Tykerb) in patients with HER2-amplified metastatic colorectal cancer.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the ideal therapy for melanoma in the adjuvant setting.

Sequential Therapy for Metastatic Pancreatic Cancer

Ann W. Silk, MD, discusses preliminary results of the CAPRA trial, a phase 1B study of intratumoral coxsackievirus A21 (CVA21; CAVATAK) and systemic pembrolizumab in patients with advanced melanoma.

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.